Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

MRKMerck Sharp & Dohme LLCSigning up patients

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Follicular Lymphoma

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Aug 13, 2026 · was worth 5, fading over time

    +1.9
Worry score2

Score over time

Stage
Phase 2/3
Patients
960 (planned)
Started
Jun 22, 2026
Main results expected
Jul 23, 2032
Fully finished
Jul 23, 2035
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1: Number of Participants Who Experience an Adverse Event (AE)

    Measured over: Up to approximately 15 months

  • Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE

    Measured over: Up to approximately 12 months

  • Part 1: Number of Participants Who Experience Dose Limiting Toxicity (DLT)

    Measured over: Up to approximately 36 days

  • Part 1: Complete Response (CR) Rate

    Measured over: Up to approximately 60 months

  • Part 2: Progression-Free Survival (PFS)

    Measured over: Up to approximately 63 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT07634471 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT07634471) ↗